Stock Ratings / Health Care / WGS / financials

ADUS (69) PRVA (57) TDOC (56) AVAH (65) ⌘ Pro Terminal →

GeneDx Holdings Corp. (Class A) (WGS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$71.02 +9.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

GeneDx Holdings Corp. (Class A) (WGS) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $2.12B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for WGS)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How WGS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$14.3M (3.3% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $202.6M

FY24

Rev $305.4M

FY25

Rev $427.5M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$427.5M	69.7%	-3.1%	-$21.0M	$14.3M	-4.1%
FY 2024	$305.4M	63.6%	-7.6%	-$52.3M	-$34.0M	-8.7%
FY 2023	$202.6M	69.7%	-80%	-$175.8M	-$180.1M	-4.1%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring WGS)

✓Walkthrough of WGS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

WGS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.93%📐 HORIZONTAL RANGE

2026-10-30O $69.32H $71.02L $66.80C $71.02VOL 886.0K

RES: $124.0SUP: $54.77SMA50: $79.04SMA200: $71.93

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WGS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 WGS Butterfly Map → + Track WGS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +40.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on WGS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for WGS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for WGS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WGS)

Health Care Rank #224 of 1016 ⚔️ ADUS vs WGS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (WGS vs. ADUS, PRVA, TDOC, AVAH)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, GeneDx Holdings Corp. (Class A) (WGS) ranks #224 by composite RQD confidence (58/100, grade D+) and #253 by equity capitalization ($2.12B). Within this direct 5-issuer industry benchmark cohort, ADUS leads on earnings valuation at 24.2x trailing P/E, while AVAH leads on capital efficiency and profitability with 15.7% ROIC and 33.3% gross margin. ADUS currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with WGS at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
WGS ACTIVE GeneDx Holdings Corp. (Class A)	D+	58/100	—	69.7%	-4.1%	+9.79%	$2.12B	Benchmark Subject
ADUS Addus HomeCare Corporation	C+	69/100	24.2x	32.5%	9.1%	+1.77%	$2.32B	/adus-vs-wgs →
PRVA Privia Health Group Inc.	D+	57/100	122.6x	—	10.5%	+0.71%	$2.81B	/prva-vs-wgs →
TDOC Teladoc Health Inc.	D+	56/100	—	—	-17.0%	+26.89%	$1.59B	/tdoc-vs-wgs →
AVAH Aveanna Healthcare Holdings Inc.	C	65/100	—	33.3%	15.7%	+1.53%	$2.89B	/avah-vs-wgs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001818331

In its most recent audited fiscal period (FY2025, filed 2025-12-31), GeneDx Holdings Corp. (Class A) (WGS) reported GAAP revenue of $427.5M (+40.0% vs. FY2024 revenue of $305.4M , and +111.1% cumulative change since FY2023) , GAAP net income of -$21.0M, operating cash flow of $33.3M, and free cash flow of $14.3M (+142.0% YoY). On the balance sheet, WGS closed FY2025 with $523.7M in total assets against $48.2M in total debt (Altman Z-Score: 3.32, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$427.5M	-$21.0M	$33.3M	$14.3M	$523.7M	$48.2M
FY2024 (FY)	2024-12-31	$305.4M	-$52.3M	-$28.5M	-$34.0M	$419.4M	$51.9M
FY2023 (FY)	2023-12-31	$202.6M	-$175.8M	-$180.1M	-$180.1M	—	—

3. WGS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WGS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, GeneDx Holdings Corp. (Class A) (NASDAQ: WGS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $71.02 (+9.79% 1D, market cap $2.12B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, WGS ranks #224 in composite RQD confidence.

How does WGS compare to ADUS and PRVA in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), WGS carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of 69.7%, and ROIC of -4.1%. By comparison, ADUS (Addus HomeCare Corporation) holds a C+ grade (69/100 RQD, P/E 24.2x, ROIC 9.1%, cap $2.32B) and PRVA (Privia Health Group Inc.) posts a D+ grade (57/100 RQD, P/E 122.6x, ROIC 10.5%, cap $2.81B). Among the 5-stock peer group, ADUS leads on earnings multiple (24.2x) while AVAH leads on capital efficiency (15.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for WGS?

Per WGS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818331), GeneDx Holdings Corp. (Class A) generated $427.5M in revenue (+40.0% YoY), -$21.0M in net income, and $14.3M in free cash flow against $523.7M in total assets and $48.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is WGS trading relative to its 50-day, 200-day, and 52-week technical levels?

WGS last traded at $71.02 (+9.79% on volume of 921,832 shares), positioning the stock -10.15% below its 50-day simple moving average ($79.04) and -1.27% below its 200-day simple moving average ($71.93). Across its 52-week range of $32.21 to $170.87, WGS sits at the 28.0% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($62.14 to $79.90).